Polifeprosan 20, 3.85% carmustine slow-release wafer in malignant glioma: Evidence for role in era of standard adjuvant temozolomide

Lawrence Kleinberg

Research output: Contribution to journal › Review article › peer-review

9 Scopus citations

Fingerprint

Dive into the research topics of 'Polifeprosan 20, 3.85% carmustine slow-release wafer in malignant glioma: Evidence for role in era of standard adjuvant temozolomide'. Together they form a unique fingerprint.

Medicine & Life Sciences